Sequencing and phylogenetic analysis of the ORF3a gene variant B.1.1.7 SARS-CoV-2 virus

The problem of "new" infectious diseases has now acquired particular relevance for national and international health systems. One of these infections is the SARS-CoV-2 coronavirus. Due to the rapid spread of a new type of coronavirus in the world, molecular genetic studies of this virus are of great importance. This will help to understand the nature of the virus and develop antiviral drugs to prevent the disease. The aim is to identify a missense mutation in the ORF3 gene of the studied coronavirus strain SARS-CoV-2/human/KAZ/Britain. This paper presents the results of the development and sequencing of the ORF3 gene of the coronavirus strain SARS-Cov-2/human/KAZ/Britain. For the development and sequencing by the Sanger method of the ORF3 gene, 4 pairs of primers were developed, with an overlap of 100-150 bp. The changes in the ORF3 gene compared to other strains whose data were obtained from the GISAID database were analyzed.  As a result, the obtained amino acid sequences of the ORF3a gene of variant B.1.1.7 were compared with the reference strain HCoV-19/Wuhan/Hu-1/2019, where one mutation was determined at position 149: W (tryptophan) → L (leucine). The phylogenetic affiliation of the studied virus strain was also determined, where the genetic distance between the studied strains of the SARS-CoV-2 virus was determined. Thus, the greatest similarity with the studied strain were: HCoV-19/Wuhan/Hu-1/2019, HCoV-19/England/MILK-9E05B3/2020, HCoV-19/Japan/IC-0446/2020, HCoV-19/Germany/NI-IOV-MHH15/2020, and the strain HCoV-19/Argentina/PAIS-F0418/2021 significantly distanced itself from the SARS-CoV-2/human/KAZ/Britain strain.

1. Lu H., Stratton C.W., Tang Y.W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. // J Med Virol. – 2020. 92(4). - Р.401-402. doi:10.1002/jmv.25678

2. Lam S., Lombardi A., Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. // Eur J Pharmacol. – 2020. - 886 (5) 173451. doi:10.1016/j.ejphar.2020.173451

3. COVID-19 – China. Pneumonia of unknown cause – China (who.int)

4. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X.,Wang D., Xu W., Wu G., Gao G.F., Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. // N Engl J Med. – 2020. 382(8). – P. 727-733. doi:10.1056/NEJMoa2001017

5. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., Yuan M.L., Zhang Y.L., Dai F.H., Liu Y., Wang Q.M., Zheng J.J., Xu L., Holmes E.C., Zhang Y.Z. A new coronavirus associated with human respiratory disease in China. // Nature. – 2020. 579 (7798). – P. 265-269. doi:10.1038/s41586-020-2202-3

6. Emam M., Oweda M., Antunes A., El-Hadidi M. Positive selection as a key player for SARS-CoV-2 pathogenicity: Insights into ORF1ab, S and E genes. // Virus Res. – 2021. 302:198472. doi:10.1016/j.virusres.2021.198472

7. SeyedAlinaghi S., Mirzapour P., Dadras O. et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. // Eur J Med Res. - 2021. 26(1). 51. doi:10.1186/s40001-021-00524-8

8. Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., Meng J., Zhu Z., Zhang Z., Wang J., Sheng J., Quan L., Xia Z., Tan W., Cheng G., Jiang T. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. // Cell Host Microbe. – 2020. 27(3). - P.325-328. doi:10.1016/j.chom.2020.02.001

9. Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. // Nature. - 2020. 583. – P. 459–468. doi:10.1038/s41586-020-2286-9

10. Ren, Y., Shu, T., Wu, D. et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. // Cell Mol Immunol. – 2020. 17. – P. 881–883. doi:10.1038/s41423-020-0485-9

11. Issa E, Merhi G, Panossian B, Salloum T, Tokajian S. SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis.” // mSystems. – 2020. 5(3). doi:10.1128/mSystems.00266-20

12. Scott C., Griffin S. Viroporins: structure, function and potential as antiviral targets. // J Gen Virol. - 2015 96(8). – P. 2000-2027. https://doi.org/10.1099/vir.0.000201

13. Bianchi M., Borsetti A., Ciccozzi M., Pascarella S. SARS-CoV-2 ORF3a: Mutability and function. // Int J Biol Macromol. – 2021. 170. - P. 820-826. doi: 10.1016/j.ijbiomac.2020.12.142

14. Padhan K., Tanwar C., Hussain A., Hui P.Y., Lee M.Y., Cheung C.Y., Peiris J.S.M., Jameel S. Severe acute respiratory syndrome coronavirus Orf3a protein interacts with caveolin. // J Gen Virol. – 2007. 88(11). – P. 3067-3077. https://doi.org/10.1099/vir.0.82856-0

15. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., Marrama D., de Silva A.M., Frazier A., Carlin A.F., Greenbaum J.A., Peters B., Krammer F., Smith D.M., Crotty S., Sette A. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. // Cell. – 2020. 181(7). – P.1489-1501. doi:10.1016/j.cell.2020.05.015

16. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Peñaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C, Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Günther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. // Science. - 2003. 300(5624). –Р.1394-9. doi:10.1126/science.1085952

17. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., Roper R.L.. The Genome sequence of the SARS-associated coronavirus. // Science. – 2003. 300(5624). –Р.1399-404. doi:10.1126/science.1085953

18. Tan Y.J., Teng E., Shen S., Tan T.H., Goh P.Y., Fielding B.C., Ooi E.E., Tan H.C., Lim S.G., Hong W. A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis. // J Virol. – 2004. 78(13). – Р.6723-34. doi:10.1128/JVI.78.13.6723-6734.2004

19. Zhang J., Ejikemeuwa A., Gerzanich V., Nasr M., Tang Q., Simard J.M., Zhao R.Y. Understanding the Role of SARS-CoV-2 ORF3a in Viral Pathogenesis and COVID-19. // Front Microbiol. – 2022. 13:854567. doi:10.3389/fmicb.2022.854567

20. Zhong X., Guo Z., Yang H., Peng L., Xie Y., Wong T.Y., Lai S.T., Guo Z. Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients. // J Gen Virol. – 2006. 87(Pt 2). –Р.369-373. https://doi.org/10.1099/vir.0.81078-0

21. Tamura K., Stecher G., and Kumar S. (2021). MEGA 11: Molecular Evolutionary Genetics Analysis Version 11. // Molecular Biology and Evolution. – 2021. 38(7). - P.3022-3027. doi:10.1093/molbev/msab120

22. Tamura K., Nei M., Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. // Proc Natl Acad Sci USA. – 2004. 101(30). – P.11030-5. https://doi.org/10.1073/pnas.0404206101

23. Tzou P.L., Tao K., Nouhin J., Rhee S.Y., Hu B.D., Pai S., Parkin N., Shafer R.W. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. // Viruses. – 2020. 12(9). – Р. 1006. doi:10.3390/v12091006

24. Chu D.K.W., Hui K.P.Y., Gu H., Ko R.L.W., Krishnan P., Ng D.Y.M., Liu G.Y.Z., Wan C.K.C., Cheung M.C., Ng K.C., Nicholls J.M., Tsang D.N.C., Peiris M., Chan M.C.W., Poon L.L.M. Introduction of ORF3a-Q57H SARS-CoV-2 Variant Causing Fourth Epidemic Wave of COVID-19, Hong Kong, China. // Emerg Infect Dis. – 2021. 27(5). – Р.1492-1495. doi:10.3201/eid2705.210015

25. Kern D.M., Sorum B., Mali S.S., Hoel C.M., Sridharan S., Remis J.P., Toso D.B., Kotecha A., Bautista D.M., Brohawn S.G. Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs. // Nat Struct Mol Biol. – 2021. 28(8). – Р.702. doi:10.1101/2020.06.17.156554

26. Desingu P.A., Nagarajan K., Dhama K. Emergence of Omicron third lineage BA.3 and its importance. // J Med Virol. – 2022. 94(5). –Р.1808-1810. doi:10.1002/jmv.27601

27. Abdullah F., Myers J., Basu D., Tintinger G., Ueckermann V., Mathebula M., Ramlall R., Spoor S., de Villiers T., Van der Walt Z., Cloete J., Soma-Pillay P., Rheeder P., Paruk F., Engelbrecht A., Lalloo V., Myburg M., Kistan J., van Hougenhouck-Tulleken W., Boswell M.T., Gray G., Welch R., Blumberg L., Jassat W. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. // Int J Infect Dis. – 2022. – Р.116:38-42. doi:10.1016/j.ijid.2021.12.357

28. Davarinejad H., Huang Y.C., Mermaz B., LeBlanc C., Poulet A., Thomson G., Joly V., Muñoz M., Arvanitis-Vigneault A., Valsakumar D., Villarino G., Ross A., Rotstein B.H., Alarcon E.I., Brunzelle J.S., Voigt P., Dong J., Couture J.F., Jacob Y. The histone H3.1 variant regulates TONSOKU-mediated DNA repair during replication. // Science. – 2022. 375(6586). – P.1281-1286. doi:10.1126/science.abm5320